Company Overview and News
If we look at the historical performance of precious metals to markets, we see that gold has been closely tracking market volatility. The recent upheaval in the markets, led by Syria tensions, supported precious metals. Also, the earlier trade war fears with China lifted precious metals higher.
Unrest in Syria played a role in precious metals rising on Friday, April 13. The day before, Donald Trump discussed how to address a recent Syrian poison gas attack. He threatened missile strikes, which were eventually carried out, on Saturday.
April 17, 2018: Here are four stocks trading with heavy volume among 41 equities making new 52-week lows in Tuesday’s session. On the NYSE advancers led decliners by about 11 to 4 and on the Nasdaq, advancers led decliners by about 5 to 2.
Overall, gold has been rising in 2018, mainly due to the geopolitical tensions that keep increasing. First, we had fears of a US-China trade war, and now we have the Syrian chemical attack and subsequent air strikes. Another crucial element is the decline of the US dollar, which we’ll look at in the next part of this series.
The Fed minutes from its policy meeting on March 20–21 were released on April 11, 2018. These minutes were slightly more hawkish than expected. In the March meeting minutes, the FOMC (Federal Open Market Committee) staff review of the economy was stronger than the review presented at the January meeting. The short-term real GDP growth expectation was revised lower due to softness in recent economic data.
In this part of our series, we’ll look at the correlation between gold and four mining stocks: Royal Gold (RGLD), Goldcorp (GG), Sibanye Gold (SBGL), and Gold Fields (GFI). Mining stocks mostly move with gold prices, but not always. Among these four miners, Gold Fields has shown the highest correlation with gold, while Royal Gold has seen the lowest correlation with gold on a YTD (year-to-date) basis.
April 9, 2018: Here are four stocks trading with heavy volume among 77 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by more than 8 to 7 and on the Nasdaq, advancers led decliners by about 4 to 3.
April 5, 2018: Here are four stocks trading with heavy volume among 42 equities making new 52-week lows in Thursday’s session. On the NYSE advancers led decliners by about 7 to 3 and on the Nasdaq, advancers led decliners by about 9 to 5.
Most mining companies saw an upswing in prices on Thursday, March 29, 2018, since silver rose and gold was only marginally lower. Most of the time, miners follow the price movements of precious metals, but that sometimes can change.
NEW YORK (Reuters) - A research scientist at Massachusetts Institute of Technology was sentenced on Friday to 15 months in prison after admitting to insider trading on a mining company merger that his wife, a corporate lawyer, had been working on.
A crucial factor that could be behind the loss in precious metals on Wednesday was the rebound in the US dollar. The US Dollar Index, which is depicted by the DXY Currency Index (UUP), increased 0.82% on Wednesday. It also stands at a five-day trailing gain of 0.31%. The rise of the US dollar is often detrimental for precious metals, as they are all dollar-denominated assets. The higher the dollar, the more expensive it gets for buyers from other countries to invest in dollar and dollar assets.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET